Subchronic Oral Toxicity of Sodium p-Hydroxybenzoate in Sprague-Dawley Rats

Xiaoli Fan1, Hengzhi Song2, Xiaotian Xu2, Xi Lu2, Yuhui Wang2* and Xiaoqun Duan1,2*

1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China, 2College of Pharmacy, Guilin Medical University, Guilin, China

p-Hydroxybenzoic acid (p-HBA), which exists extensively in plants, is well known for its anti-inflammatory effects, but various adverse side effects have also been reported. Previous research has found that acid translated to its sodium salt improves the safety profile of compounds. Therefore, we hypothesized that p-HBA translated to sodium p-hydroxybenzoate would improve its safety profile. In the present study, we evaluated the toxicity of sodium p-hydroxybenzoate after 90 days of repeated oral toxicity experiments according to OECD guidelines in male and female Sprague–Dawley rats. Sodium p-hydroxybenzoate was administered orally to SD rats at doses of 0, 125, 250, and 500 mg/kg body weight (BW)/day for 90 days. All animals survived to the end of the study, and no sodium p-hydroxybenzoate treatment-associated mortality or clinical changes were observed during the study period. Sodium p-hydroxybenzoate did not promote any clinical signs of toxicologically relevant effects, including changes in body weight, food intake and urinalysis parameters, in male or female SD rats. Dose-related alterations in hematological parameters, organ weights and histopathological findings in hepatic tissue were examined in animals of both sexes in the 500 mg/kg BW/day group. Based on the study, the no-observed-adverse-effect level (NOAEL) for sodium p-hydroxybenzoate was determined to be 250 mg/kg BW/day in both male and female rats.

Keywords: sodium p-hydroxybenzoate, toxicity, NOAEL, safety assessment, p-hydroxybenzoic acid

INTRODUCTION

p-Hydroxybenzoic acid (p-HBA), a monohydroxy phenolic derivative of phenolic acid containing a C6-C1 carbon skeleton, exists extensively in plants (Kim et al., 2020). Various studies have confirmed that p-HBA has therapeutic advantages such as antibacterial (Qin et al., 2020; Liu et al., 2021), anticancer (Spatafora and Tringali, 2012), antioxidative (Winter et al., 2017) and anti-inflammatory activities (Rakesh et al., 2018; Sabater et al., 2019). Previously, our research group found p-HBA was more effective than mesalazine in DSS-induced ulcerative

Abbreviations: A/G, albumin/globulin ratio; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BAS, basophil count; CI, chloride; EOS, eosinophil count; HCT, hematocrit; HGB, hemoglobin; K, potassium; LYM, lymphocyte count; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MON, monocyte count; Na, sodium; NEU, neutrophil count; NOAEL, the no-observed-adverse-effect level; PLT, platelet count; PT, prothrombin time; RBC, red blood cell count; RDW%, red blood cell distribution width; WBC, white blood cell count.
colitis (UC) of C57BL/6 mice. However, the safety profile of p-HBA limits its use for developing new drugs; for example, the oral 50% lethal dose (LD50) of p-HBA in rats is approximately 2,000 mg/kg, and adverse effects in response to p-HBA have been reported, including infertility in males and breast cancer in females (Asif et al., 2021). Therefore, maintaining the pharmaceutical effect while improving the safety of p-HBA would facilitate the development of clinical drugs in the future.

Previous research has revealed that acid translation to its sodium salt would represent a good approach for improving the safety profile and stability of compounds, such as diclofenac. Diclofenac is a nonsteroidal anti-inflammatory drug (Coxib et al., 2015). Therefore, we speculated that the safety profile would be improved and that the pharmaceutical effect would be maintained if p-HBA was translated into sodium p-hydroxybenzoate.

Sodium benzoate is typically used as an antimicrobial additive for food and in the pharmaceutical industry (Yadav et al., 2016). However, there are limited references regarding the toxicological and safety information of sodium p-hydroxybenzoate. In our previous acute oral toxicity experiments, the LD50 of sodium p-hydroxybenzoate was greater than 5,000 mg/kg. Therefore, in the present study, we investigated the toxicity of sodium p-hydroxybenzoate using a 90-days subchronic oral toxicity test in Sprague–Dawley (SD) rats to determine toxicological profiles and establish the no-observed-adverse-effect level (NOAEL). This study represents the first safety profiling of sodium p-hydroxybenzoate in accordance with the Economic Cooperation and Development (OECD) guideline 408 (OECD, 2018). Our findings provide an imperative reference for evaluating the safety of sodium p-hydroxybenzoate.

MATERIALS AND METHOD

Reagents
Sodium p-hydroxybenzoate (LOT NO.: Y10S6K3245, purity: 98.5%) (Figure 1) was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (Shanghai, China). In this experiment, sodium p-hydroxybenzoate was suspended in distilled water by vortexing and sonication, and dose formulations were prepared on the day of administration.

Experimental Animals and Their Maintenance
Eighty male and female SD rats (40 each; 5 weeks old) were obtained from Hunan SJA Laboratory Animal Co. Ltd. under license number SCXK (YUE) 2008–2002 and were used for the 90-days subchronic toxicity study. All procedures in this experiment were strictly reviewed and approved by the Animal Ethics Committee of Guilin Medical University (animal protocol approval number, GLMC201703011). The animals were acclimated for at least 1 week to the laboratory environment before the study, and then they were housed individually in stainless steel wire mesh cages.

At the beginning of the study, all animals were healthy, the body weights were within ±20% of the mean body weight for each sex, and the body weight range at 6 weeks of age was 184–222 g for males (mean 206.5 g) and 160–209 g for females (mean 182.95 g). The animals were housed in an animal room under controlled environmental conditions: 20–22 °C with a relative humidity of 55–65%, air ventilation 18 times per hour, and a 12 h light/dark cycle with standard diet and water. The cages and padding were changed twice a week. Before the experiments, healthy SD rats were randomly divided into four groups with 10 females and 10 males each and measured before starting the administration.

Study Design and Dose Level
This study was performed in accordance with the OECD Test Guidelines (Test NO. 408: repeated dose 90-days oral toxicity study in rodents) with slight modifications. This study was performed at the Animal Center of Guilin Medical University, and the dose volume administered during the subchronic oral toxicity study was determined by the acute oral toxicity study. Sodium p-hydroxybenzoate was dissolved in distilled ultrapure water and then administered to animals via oral gavage once daily for a period of 90 consecutive days at concentrations of 0, 125, 250, and 500 mg/kg BW/day in a volume of 10 ml/kg, and the vehicle served as a control.

During the study period, all animals were examined for signs of morbidity and mortality twice a day. General clinical observations were made and recorded at the same time once a day, and detailed clinical observations were made of all animals once a week. These observations were made outside the home cage and were carefully recorded. Observations included behavioral patterns, physical appearance, and other toxicity-related symptoms. The home cage observations included posture, convulsions, and abnormal behavior.

Body Weight and Food Intake
Body weights were recorded for all animals on the first day of the experiment and subsequently once a week thereafter, and the measurement of feed consumption was monitored weekly throughout the entire study.

![FIGURE 1 | Chemical structure of sodium p-hydroxybenzoate.](https://example.com/figure1.png)
Hematology and Clinical Biochemistry
At the end of the study, all rats were fasted overnight before collecting blood samples for hematology and clinical biochemistry. Blood samples were obtained from the hearts of animals by intracardiac withdrawal. The hematology parameters were analyzed using an automatic hematology analyzer (XN-9000, Sysmex Corp. Japan), including hemoglobin concentration (HGB), red blood cell count (RBC), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), hematocrit value (HCT), white blood cell count (WBC), red blood cell distribution width (RDW), platelet count (PLT), white blood cell count (WBC), and differential leukocyte count including neutrophils (NEUT), eosinophils (EOS), basophils (BASO), monocytes (MONO) and lymphocytes (LYM).

Blood samples for coagulation tests were used to determine the prothrombin time (PT) and activated partial thromboplastin time (APTT) using a blood coagulation analyzer (CA-1500, Sysmex Corp. Japan).

The following serum biochemistry parameters were evaluated using an automatic chemistry analyzer (Cobas 8,000, Roche Diagnostics, IN, United States): aspartate aminotransferase (AST), alanine aminotransferase (Altman et al.), alkaline phosphatase (ALP), total bile acid (TBA), total cholesterol (TCCHO), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), phospholipid (PL), total bilirubin (T-BIL), glucose (GLU), blood urea nitrogen (BUN), urea, creatinine (CRNN), total protein (TP), albumin (ALB), globulin, A/G ratio (A/G), sodium (Na), potassium (K) and chloride (Cl).

Serum thyroid-stimulating hormone levels of triiodothyronine (T3), thyroxine (T4) and thyroid-stimulating hormone (TSH) were assessed using an automatic chemiluminescence immunoassay analyzer (COBAS 8000 e801, Roche Diagnostics, IN, United States).

Urinalysis
At the end of the study, a metabolic cage used for urine collection was used for urinalysis. Urine pH, density, protein, ketones, glucose, occult blood, urobilinogen, bilirubin, urinary sediments and cast were analyzed using a Toshiba 200FR NEO chemistry analyzer (Toshiba Co., Tokyo, Japan).

Organ Weight and Pathology Examination
After collecting the blood samples, all rats were subjected to gross necropsy. Then, the primary organs were excised and weighed, such as the brain, heart, spleen, liver, lungs, kidneys, adrenal glands, thymus, testis (male), epididymis (male), ovaries (female) and uterus (female). The relative organ weights of each rat were then calculated (organ weight as a % of body weight).

In addition to these organs, trachea, thyroid, parathyroid gland, aorta, esophagus, stomach, small and large intestines, pancreas, urinary bladder, prostate, cervical and mesenteric lymph nodes, sternum, sciatic nerve and mammary glands were fixed in 10% neutral-buffered formalin. According to the recommendations of the OECD Guideline 407 (OECD, 2008), all preserved organs and tissues in the control and highest dose groups (500 mg/kg group) were subjected to full histopathology. Tissues were routinely made into paraffin-embedded sections and stained with hematoxylin and eosin (HE) for histopathological evaluation. If treatment-related changes appeared at the highest dose, the relevant tissues from the lower dose groups were also examined.

Statistical Analysis
All experimental data and statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software version 22.0 (IBM, Armonk, NY, United States). Levene’s test was used to test the assumption of homogeneity of variance. If the assumption of homogeneity of variance was met, the post hoc Bonferroni test was used to determine which groups that were significantly different from the control group. When statistically significant differences were observed, the Dunnett T3 test was employed for comparisons between the control and treatment groups. All data are presented as the mean ± standard deviation in each group, and p-values < 0.05 were considered statistically significant.

RESULT
Mortality and Clinical Signs
All animals survived, and no abnormal clinical signs associated with sodium p-hydroxybenzoate treatment were observed...
among any of the groups in either females or males. Specifically, compared to the control group, SD rats exhibited no significant abnormalities on ophthalmology examination in either sex. Furthermore, no abnormal clinical signs or changes were found in any treated SD rats in the clinical observations made outside the home cage.

### Body Weight and Feed Consumption

To further study the influence of sodium p-hydroxybenzoate on the rat model, we recorded changes in body weight (Figure 2) and food consumption (Figure 3) in the presence and absence of sodium p-hydroxybenzoate. Regardless of sex, all rats gained weight, and body weight increased in a time-dependent manner throughout the study. No significant differences in body weight were noted between the control and treated groups of male and female rats throughout the 90-days experimental period.

Similarly, the food consumption presented in Figure 3 shows no difference between the control and sodium p-hydroxybenzoate-treated groups. All experimental subjects exhibited a similar and slightly decreasing trend in feed consumption in both male and female rats in all groups during the study period.

### Hematological Parameters

Hematology-related markers are important indicators of pathophysiological status (Li et al., 2021). Therefore, to further determine the pathophysiological status of the animals, we next examined the hematological parameters of the rats. The influence of sodium p-hydroxybenzoate on the hematological parameters of male and female rats is shown in Table 1; Table 2, respectively.

First, compared to the control group, white blood cells (WBCs) in the male group at a dose of 500 mg/kg increased significantly, but this trend was not detected in female rats of any dose group. Furthermore, a significant \( (p < 0.05) \) decrease in the coagulation parameter prothrombin time (PT) was observed in the 500 mg/kg BW/day dose group compared to the control group. In females, no significant difference was observed in hematological parameters of any of the dose groups. In comparison, the

### TABLE 1 | Hematological parameters of male SD rats treated with sodium p-hydroxybenzoate for 90 days.

| Parameter | sodium p-hydroxybenzoate (mg/kg) |
|-----------|-----------------------------------|
|           | 0 | 125 | 250 | 500 |
| NO. of animals examined | 10 | 10 | 10 | 10 |
| Males | | | | |
| RBC (10^6/μL) | 9.47 ± 0.317 | 9.49 ± 0.47 | 8.99 ± 0.35 | 9.06 ± 0.83 |
| HGB (g/L) | 173.0 ± 14.93 | 169.8 ± 13.2 | 159.5 ± 9.87 | 164.4 ± 18.52 |
| HCT (%) | 52.76 ± 6.14 | 52.68 ± 2.68 | 49.48 ± 2.22 | 50.78 ± 4.21 |
| MCV (fL) | 55.6 ± 5.23 | 55.52 ± 0.60 | 55.02 ± 1.04 | 56.08 ± 1.29 |
| MCH (pg) | 18.24 ± 1.10 | 17.91 ± 1.04 | 17.72 ± 0.84 | 18.13 ± 1.28 |
| MCHC (g/L) | 329.1 ± 16.45 | 322.5 ± 16.15 | 322.1 ± 12.55 | 323.0 ± 17.60 |
| RDW (%) | 13.2 ± 0.59 | 13.69 ± 0.68 | 13.83 ± 0.57 | 13.26 ± 0.56 |
| PLT (10^4/μL) | 116.24 ± 8.98 | 119.49 ± 22.40 | 110.18 ± 11.78 | 107.68 ± 12.45 |
| WBC (10^3/μL) | 5.12 ± 0.97 | 9.36 ± 1.59 | 9.22 ± 0.66 | 9.68 ± 1.32* |
| Neu (10^3/μL) | 1.84 ± 0.45 | 1.79 ± 0.23 | 1.812 ± 0.28 | 1.871 ± 0.64 |
| Lym (10^3/μL) | 6.93 ± 1.76 | 8.37 ± 2.14 | 7.576 ± 1.13 | 7.629 ± 0.69 |
| Mon (10^3/μL) | 0.275 ± 0.104 | 0.309 ± 0.109 | 0.325 ± 0.087 | 0.379 ± 0.156 |
| eosinophils | 0.132 ± 0.053 | 0.135 ± 0.058 | 0.128 ± 0.043 | 0.134 ± 0.055 |
| BAS (10^3/μL) | 0.026 ± 0.019 | 0.023 ± 0.016 | 0.004 ± 0.005 | 0.018 ± 0.013 |
| PT (sec) | 14.90 ± 0.67 | 14.26 ± 0.66 | 14.68 ± 0.95 | 13.76 ± 0.84* |
| APTT (sec) | 15.86 ± 1.21 | 16.11 ± 0.98 | 16.44 ± 0.72 | 16.09 ± 1.30 |

RBC, red blood cell count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW%, red blood cell distribution width; PLT, platelet count; WBC, white blood cell count; NEU, neutrophil count; LYM, lymphocyte count; MON, monocyte count; EOS, eosinophil count; BAS, basophil count; PT, prothrombin time; APTT, activated partial thromboplastin time.

Data are expressed as means ± SD. \( p < 0.05 \), (significantly different from the control group).

One-way ANOVA test and Bonferroni test.
500 mg/kg BW/day dose significantly increased WBCs, which are regarded as an effective marker of inflammation (Karino et al., 2015), indicating that the 500 mg/kg dose may cause hematological toxicity in male rats. PT is a significant coagulation biomarker due to its direct correlation to the physiological clotting time, and prolonged PT represents impairment of coagulation function (Saha et al., 2021). In this study, since the PT did not change in the 500 mg/kg BW/day dose group in females, this was considered to be due to individual differences.

### Clinical Biochemistry Parameters

The serum biochemical parameters of male and female rats are shown in Table 3 and Table 4, respectively. Compared to the control group, a reduction in urea ($p < 0.05$) was only found in the 250 mg/kg BW/day male group, which is considered incidental.

#### TABLE 2 | Hematological parameters of female SD rats treated with sodium p-hydroxybenzoate for 90 days.

| Parameter | sodium p-hydroxybenzoate (mg/kg) |
|-----------|---------------------------------|
|           | 0 | 125 | 250 | 500 |
| NO. of animals examined | 10 | 10 | 10 | 10 |
| Females | | | | |
| RBC (10^6/μL) | 8.10 ± 0.28 | 7.97 ± 0.75 | 7.99 ± 0.40 | 7.76 ± 0.99 |
| HGB (g/L) | 158.4 ± 6.92 | 157.2 ± 13.30 | 153.9 ± 13.05 | 154.4 ± 19.50 |
| HCT (%) | 47.41 ± 1.78 | 47.88 ± 3.95 | 46.24 ± 2.90 | 46.31 ± 5.96 |
| MCV (fl) | 58.56 ± 0.96 | 60.19 ± 2.58 | 57.84 ± 1.38 | 59.74 ± 1.87 |
| MCH (pg) | 19.55 ± 0.98 | 19.76 ± 0.36 | 19.22 ± 0.93 | 19.94 ± 0.72 |
| MCHC (g/L) | 333.9 ± 11.73 | 328.6 ± 9.85 | 332.2 ± 10.84 | 333.7 ± 7.57 |
| RDW (%) | 13.64 ± 0.33 | 13.79 ± 1.20 | 13.34 ± 0.51 | 13.7 ± 1.26 |
| PLT (10^4/μL) | 101.8 ± 5.94 | 102.1 ± 8.86 | 107.0 ± 3.89 | 101.9 ± 7.21 |
| WBC (10^3/μL) | 8.99 ± 0.86 | 8.82 ± 1.78 | 8.73 ± 0.96 | 8.63 ± 1.94 |
| NEU (10^3/μL) | 0.86 ± 0.26 | 0.97 ± 0.38 | 1.04 ± 0.35 | 0.83 ± 0.28 |
| LYM (10^3/μL) | 3.75 ± 1.06 | 3.64 ± 0.51 | 4.12 ± 1.63 | 4.04 ± 1.15 |
| MON (10^3/μL) | 0.202 ± 0.156 | 0.169 ± 0.060 | 0.186 ± 0.059 | 0.198 ± 0.097 |
| EOS (10^3/μL) | 0.082 ± 0.019 | 0.074 ± 0.016 | 0.021 ± 0.017 | 0.018 ± 0.015 |
| BAS (10^3/μL) | 14.66 ± 1.10 | 14.02 ± 1.16 | 15.26 ± 1.15 | 14.34 ± 1.03 |
| PT (sec) | 15.48 ± 0.87 | 15.06 ± 1.15 | 14.95 ± 1.14 | 15.95 ± 0.83 |

#### TABLE 3 | Biochemical parameters of male SD rats treated with sodium p-hydroxybenzoate for 90 days.

| Parameter | sodium p-hydroxybenzoate (mg/kg) |
|-----------|---------------------------------|
|           | 0 | 125 | 250 | 500 |
| NO. of animals examined | 10 | 10 | 10 | 10 |
| Males | | | | |
| ALT (U/L) | 29.3 ± 3.59 | 30.7 ± 2.21 | 31.0 ± 6.62 | 27.3 ± 1.77 |
| AST (U/L) | 96.9 ± 2.85 | 95.3 ± 5.83 | 96.0 ± 10.47 | 93.1 ± 5.97 |
| Glucose (mmol/L) | 6.51 ± 0.25 | 7.01 ± 0.89 | 6.57 ± 1.31 | 6.77 ± 0.76 |
| Urea (mmol/L) | 7.34 ± 1.51 | 7.07 ± 0.79 | 5.97 ± 0.79* | 7.02 ± 0.89 |
| Creatinine (μmol/L) | 43.3 ± 7.57 | 40.7 ± 3.34 | 40.2 ± 2.10 | 42.9 ± 3.07 |
| Total cholesterol (mmol/L) | 1.74 ± 0.17 | 1.71 ± 0.20 | 1.65 ± 0.35 | 1.43 ± 0.21* |
| Triglyceride (mmol/L) | 1.25 ± 0.20 | 1.10 ± 0.13 | 1.32 ± 0.10 | 1.22 ± 0.10 |
| Total Bilirubin (μmol/L) | 1.84 ± 0.12 | 1.81 ± 0.09 | 1.87 ± 0.24 | 1.68 ± 0.28 |
| Total Protein (g/L) | 63.6 ± 2.80 | 62.1 ± 1.66 | 61.7 ± 1.64 | 61.4 ± 2.88 |
| Albumin (g/L) | 41.7 ± 1.83 | 42.4 ± 1.43 | 41.1 ± 3.21 | 41.3 ± 1.57 |
| Globulins (g/L) | 21.9 ± 2.85 | 19.7 ± 2.36 | 20.6 ± 2.67 | 20.1 ± 2.60 |
| A/G (%) | 1.94 ± 0.28 | 2.19 ± 0.32 | 2.04 ± 0.36 | 2.12 ± 0.29 |
| Na (mmol/L) | 143.1 ± 2.97 | 143.24 ± 3.99 | 143.1 ± 1.53 | 144.3 ± 2.04 |
| K (mmol/L) | 4.32 ± 0.60 | 4.52 ± 0.54 | 4.64 ± 0.54 | 4.57 ± 0.62 |
| Cl (mmol/L) | 101.3 ± 6.55 | 104.1 ± 6.01 | 102.7 ± 7.01 | 103.3 ± 5.66 |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; A/G, albumin/globulin ratio; K, potassium; Na, sodium; Cl, chloride.

Data are expressed as means ± SD. $p < 0.05$, (significantly different from the control group).

One-way ANOVA test and Bonferroni test.
and not dose-related because no differences were noted in the other groups. In addition, male subjects (the 500 mg/kg BW/day group) exhibited a significant (p < 0.05) decrease in total cholesterol compared to the control group, while no differences were observed in females. Despite attaining statistical significance, the cholesterol value was within normal ranges for rats. In females, total bilirubin was significantly decreased in the 500 mg/kg BW/day group compared to the control group, while no differences were noted in males. Increased bilirubin levels are associated with primary biliary cirrhosis and hepatic cholestasis (Thapa and Walia, 2007), so a decrease in total bilirubin might have a protective effect. Therefore, these changes were considered to be nonadverse and not of toxicological concern because these alterations did not occur in both sexes and were not dose-related.

Thyroid hormone levels, including triiodothyronine (T3), thyroxine (T4) and thyroid-stimulating hormone (TSH), are presented in Table 5. In this experiment, there were no differences between the sodium p-hydroxybenzoate-administered groups and the control group.

### Urinalysis

The urinalysis parameters of male and female SD rats are presented in Table 6; Table 7, respectively. Urine density and urine pH did not exhibit significant changes between the control and sodium p-hydroxybenzoate-treated groups. Meanwhile, there were no significant changes in various urinalysis parameters (protein, ketones, glucose, occult blood, urobilinogen, bilirubin) or other urine sediment parameters, such as red blood cells, white blood cells and casts, of the

| Parameter | sodium p-hydroxybenzoate (mg/kg) |
|-----------|----------------------------------|
| ALT (U/L) | 28.1 ± 1.37 27.5 ± 1.51 26.1 ± 2.69 25.9 ± 2.02 |
| AST (U/L) | 87.6 ± 7.66 94.9 ± 10.97 87.7 ± 8.26 90.0 ± 12.01 |
| Glucose (mmol/L) | 6.42 ± 1.09 6.52 ± 0.62 6.64 ± 0.71 6.58 ± 0.35 |
| Urea (mmol/L) | 7.47 ± 2.04 7.59 ± 2.19 7.43 ± 1.22 7.51 ± 0.61 |
| Creatinine (µmol/L) | 48.6 ± 12.75 49.9 ± 2.56 49.56 ± 8.65 49.67 ± 5.52 |
| Total cholesterol (mmol/L) | 1.58 ± 0.24 1.71 ± 0.15 1.61 ± 0.24 1.74 ± 0.15 |
| Triglyceride (mmol/L) | 1.03 ± 0.11 0.99 ± 0.11 1.03 ± 0.21 1.11 ± 0.10 |
| Total Bilirubin (µmol/L) | 1.81 ± 0.13 1.7 ± 0.19 1.64 ± 0.17 1.57 ± 0.13* |
| Total Protein (g/L) | 66.6 ± 1.26 67.7 ± 5.25 67.8 ± 3.22 66.8 ± 1.75 |
| Albumin (g/L) | 46.6 ± 1.58 46.9 ± 5.30 46.2 ± 3.05 45.5 ± 1.43 |
| Globulins (g/L) | 20.2 ± 1.03 20.8 ± 1.23 21.2 ± 1.32 21.0 ± 1.83 |
| A/G (%) | 2.32 ± 0.20 2.26 ± 0.30 2.19 ± 0.18 2.17 ± 0.20 |
| Na (mmol/L) | 145.1 ± 1.94 145.9 ± 1.86 145.3 ± 1.61 145.4 ± 1.29 |
| K (mmol/L) | 4.12 ± 0.82 3.9 ± 0.77 3.96 ± 0.95 4.28 ± 0.70 |
| Cl (mmol/L) | 101.3 ± 7.30 97.8 ± 5.79 99.2 ± 7.54 98.3 ± 5.70 |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; A/G, albumin/globulin ratio; K, potassium; Na, sodium; Cl, chloride.

Data are expressed as means ± SD. *p < 0.05, (significantly different from the control group).

One-way ANOVA test and Bonferroni test.
male and female rats treated with sodium p-hydroxybenzoate compared to the control groups.

### Absolute and Relative Organ Weights

The absolute and relative organ weights of male and female SD rats, including brain, heart, spleen, lung, liver, kidneys, adrenal, thymus, testis (male), epididymis (male), ovaries (female) and uterus (female), are shown in Tables 8, 9. Changes observed in organ weight are also considered toxicity indicators of compounds administered (Michael et al., 2007; Li et al., 2021), and relative organ weight values have been shown to reflect pathological changes in impaired tissues (Balogun et al., 2014; Li et al., 2014). In males, absolute epididymis weight exhibited a statistically significant \((p < 0.05)\) increase in the 500 mg/kg BW/day group compared to the control group. However, since the relative weight of the epididymis did not change and no microscopic changes were observed, this was considered to be due to individual differences and not obviously toxicity-related. In females, a significant increase in the absolute weight of the liver was detected in the 500 mg/kg BW/day group compared with the control, while the relative liver weight did not change. Changes in liver weight can occur in various hepatic diseases, such as steatosis, fibrosis and cirrhosis (Simon et al., 2020), and steatosis can increase liver weight (Molina, 2011). The above results showed that the 500 mg/kg BW/day dose might cause slight liver toxicity in female rats.

---

**TABLE 6** | Urinalysis values of male and female SD rats treated with sodium p-hydroxybenzoate for 90 days.

| sodium p-hydroxybenzoate (mg/kg) | 0 | 125 | 250 | 500 |
|----------------------------------|---|-----|-----|-----|
| NO. of animals examined          | 10| 10  | 10  | 10  |
| **Males**                        |   |     |     |     |
| Urine density                    | 1.016 ± 0.007 | 1.019 ± 0.007 | 1.016 ± 0.006 | 1.015 ± 0.005 |
| Urine pH                         | 7.15 ± 0.53   | 6.85 ± 0.75   | 7.2 ± 0.59     | 7.05 ± 0.55    |
| **Females**                      |   |     |     |     |
| Urine density                    | 1.016 ± 0.007 | 1.018 ± 0.007 | 1.014 ± 0.004 | 1.013 ± 0.004 |
| Urine pH                         | 7.10 ± 0.52   | 6.75 ± 0.63   | 6.96 ± 0.55    | 7.00 ± 0.53    |

Data are expressed as means ± SD. \(* p < 0.05\), (significantly different from the control group). One-way ANOVA test and Bonferroni test.

**TABLE 7** | Urinalysis values of male and female SD rats treated with sodium p-hydroxybenzoate for 90 days.

| Urinalysis parameters | severity scale | sodium p-hydroxybenzoate (mg/kg) |
|-----------------------|----------------|----------------------------------|
|                       |                | 0                  | 125                | 250                | 500                |
| **Male**              |                |                    |                    |                    |
| Protein               |                | 7/10               | 6/10               | 6/10               | 5/10               |
| 1+                    |                | 2/10               | 2/10               | 2/10               | 2/10               |
| 2+                    |                | 1/10               | 2/10               | 2/10               | 2/10               |
| 3+                    |                | 0/10               | 0/10               | 0/10               | 0/10               |
| Ketones               |                | 10/10              | 10/10              | 10/10              | 10/10              |
| Glucose               |                | 10/10              | 10/10              | 10/10              | 10/10              |
| Occult blood          |                | 10/10              | 10/10              | 10/10              | 10/10              |
| Urobilinogen          |                | 10/10              | 10/10              | 10/10              | 10/10              |
| Bilirubin             |                | 8/10               | 8/10               | 8/10               | 8/10               |
| 1*                   |                | 2/10               | 2/10               | 2/10               | 2/10               |
| Urinary sediments     |                | 10/10              | 10/10              | 10/10              | 10/10              |
| Red blood cell        |                | 10/10              | 10/10              | 10/10              | 10/10              |
| White blood cell      |                | 10/10              | 10/10              | 10/10              | 10/10              |
| Cast                  |                | 10/10              | 10/10              | 10/10              | 10/10              |

**Female**

| Sodium p-hydroxybenzoate (mg/kg) | 0 | 125 | 250 | 500 |
|----------------------------------|---|-----|-----|-----|
| NO. of animals examined          | 10| 10  | 10  | 10  |
| **Males**                        |   |     |     |     |
| Urine density                    | 1.016 ± 0.007 | 1.019 ± 0.007 | 1.016 ± 0.006 | 1.015 ± 0.005 |
| Urine pH                         | 7.15 ± 0.53   | 6.85 ± 0.75   | 7.2 ± 0.59     | 7.05 ± 0.55    |
| **Females**                      |   |     |     |     |
| Urine density                    | 1.016 ± 0.007 | 1.018 ± 0.007 | 1.014 ± 0.004 | 1.013 ± 0.004 |
| Urine pH                         | 7.10 ± 0.52   | 6.75 ± 0.63   | 6.96 ± 0.55    | 7.00 ± 0.53    |

No significant differences were noted in any treated groups from control group.

Protein) \(\sim 0 \text{ g/L}\), 1*: \(0.3 \text{ g/L}\), 2*: \(1.0 \text{ g/L}\), 3*: \(\geq 3.0 \text{ g/L}\).

Ketones) \(\sim 0 \text{ mmol/L}\).

Glucose) \(\sim 0 \text{ mmol/L}\).

Occult blood) \(\sim 0 \text{ cells}\).

Bilirubin) \(\sim 0 \mu\text{mol/L}\), 1*: \(8.6 \mu\text{mol/L}\).
Histopathological Survey and Gross Pathological Analysis

The necropsy results indicated no treatment-related changes had occurred in any sodium p-hydroxybenzoate-treated group. The histopathological findings are shown in Table 10. In the heart, minimal edema of the myocardial interstitium was observed in some male rats. Pulmonary and splenic congestion was observed in both sexes in the control and treatment groups. Local minimal inflammation was found in the 500 mg/kg BW/day group in both males and females in the stomach. These histopathologies were minimal and showed no significant treatment relationship between the control group and treated group. Tissue images from the control and high-dosing groups stained with H&E are shown for major representative organs (heart, brain, spleen and lung) (Figure 4). Slight edema and degeneration of renal tubular epithelial cells were observed in the 500 mg/kg BW/day male group. In the liver, hepatic sinusoid congestion was observed in both sexes in the control and treatment groups. Vacuolated degeneration was found in the 500 mg/kg BW/day group in both males and females. Tissue images of liver and kidney from the control and high-dosing groups stained with H&E are shown in Figure 5.

DISCUSSION

Sodium p-hydroxybenzoate is a sodium salt of p-hydroxybenzoic acid (p-HBA). In our previous acute oral toxicity experiment, the LD50 of p-hydroxybenzoic acid was greater than 2,000 mg/kg, while the LD50 of sodium p-hydroxybenzoate was greater than 5,000 mg/kg, the safety of oral administration is improved. However, information

| Table 8 | Absolute and relative organ weights of male SD rats treated with sodium p-hydroxybenzoate for 90 days. |
| Organs Description | sodium p-hydroxybenzoate (mg/kg) | sodium p-hydroxybenzoate (mg/kg) |
|---------------------|-----------------------------------|-----------------------------------|
|                     | 0 | 125 | 250 | 500 | 0 | 125 | 250 | 500 |
| Absolute (weight)   | | | | | | | | |
| Body weight (g)     | 569.8 ± 50.49 | 562.6 ± 30.43 | 570.4 ± 38.99 | 586.9 ± 15.96 |
| Brain (g)           | 2.05 ± 0.35 | 2.02 ± 0.34 | 1.97 ± 0.35 | 1.98 ± 0.28 |
| Heart (g)           | 1.50 ± 0.25 | 1.59 ± 0.12 | 1.46 ± 0.06 | 1.44 ± 0.02 |
| Spleen (g)          | 0.87 ± 0.24 | 0.87 ± 0.07 | 0.82 ± 0.06 | 0.83 ± 0.07 |
| Lung (g)            | 1.88 ± 0.14 | 1.78 ± 0.10 | 1.88 ± 0.25 | 1.83 ± 0.08 |
| Liver (g)           | 12.87 ± 2.31 | 12.16 ± 0.83 | 12.78 ± 0.31 | 13.29 ± 0.66 |
| Kidney (g)          | 3.09 ± 0.28 | 3.06 ± 0.13 | 2.92 ± 0.25 | 3.05 ± 0.07 |
| Adrenal (g)         | 0.072 ± 0.010 | 0.069 ± 0.014 | 0.065 ± 0.007 | 0.065 ± 0.009 |
| Thymus (g)          | 0.447 ± 0.081 | 0.426 ± 0.052 | 0.406 ± 0.087 | 0.480 ± 0.153 |
| Testis (g)          | 3.48 ± 0.24 | 3.51 ± 0.17 | 3.52 ± 0.22 | 3.62 ± 0.17 |
| Epididymis (g)      | 1.28 ± 0.33 | 1.39 ± 0.18 | 1.33 ± 0.08 | 1.57 ± 0.24* |
| Relative (organ weight to body weight) | | | | |

Values in the table indicate group means ± SD.; Number of animals (n) = 10.
*p ≤ 0.05 (significantly different from the control group).

| Table 9 | Absolute and relative organ weights of female SD rats treated with sodium p-hydroxybenzoate for 90 days. |
| Organs Description | sodium p-hydroxybenzoate (mg/kg) | sodium p-hydroxybenzoate (mg/kg) |
|---------------------|-----------------------------------|-----------------------------------|
|                     | 0 | 125 | 250 | 500 | 0 | 125 | 250 | 500 |
| Absolute (weight)   | | | | | | | | |
| Body weight (g)     | 320.2 ± 13.05 | 309.9 ± 20.27 | 323.5 ± 37.83 | 319.5 ± 22.78 |
| Brain (g)           | 1.91 ± 0.29 | 1.89 ± 0.27 | 1.95 ± 0.34 | 1.90 ± 0.35 |
| Heart (g)           | 1.07 ± 0.09 | 1.13 ± 0.17 | 1.03 ± 0.02 | 1.12 ± 0.17 |
| Spleen (g)          | 0.562 ± 0.033 | 0.580 ± 0.109 | 0.53 ± 0.02 | 0.61 ± 0.06 |
| Lung (g)            | 1.26 ± 0.19 | 1.24 ± 0.26 | 1.16 ± 0.06 | 1.26 ± 0.15 |
| Liver (g)           | 7.64 ± 0.55 | 8.01 ± 0.70 | 8.08 ± 0.36 | 8.38 ± 0.48* |
| Kidney (g)          | 1.98 ± 0.33 | 1.95 ± 0.23 | 2.05 ± 0.33 | 2.02 ± 0.32 |
| Adrenal (g)         | 0.075 ± 0.017 | 0.069 ± 0.013 | 0.067 ± 0.007 | 0.084 ± 0.009 |
| Thymus (g)          | 0.379 ± 0.063 | 0.388 ± 0.088 | 0.424 ± 0.068 | 0.368 ± 0.114 |
| Ovary (g)           | 0.134 ± 0.010 | 0.126 ± 0.017 | 0.119 ± 0.015 | 0.132 ± 0.011 |
| Uterus (g)          | 0.790 ± 0.311 | 0.826 ± 0.234 | 0.884 ± 0.160 | 0.642 ± 0.107 |
| Relative (organ weight to body weight) | | | | |

Values in the table indicate group means ± SD.; Number of animals (n) = 10.
*p ≤ 0.05 (significantly different from the control group).
Regarding subchronic toxicity is unclear. Therefore, the aim of this study was to conduct a comprehensive toxicological evaluation of sodium p-hydroxybenzoate to determine its safety for humans at chronic doses. In the present study, the 90-days repeated-dose subchronic oral toxicity of sodium p-hydroxybenzoate in SD rats was determined to evaluate its safety profile according to the OECD guideline 408. Subchronic oral toxicity studies are usually based on LD50 and ED50 calculated from acute toxicity tests (Ntchapda et al., 2014). The highest dose is usually 5–15% of LD50 (Wei et al., 2019), and the lowest dose is usually higher than the daily possible intake. As a result, in the subchronic toxicity study of sodium p-hydroxybenzoate, 0, 125, 250, and 500 mg/kg BW/day doses were used. At the end of the treatment regimen, all animals survived until necropsy without any clinical changes. Several studies have demonstrated that adverse effects of p-HBA cause male infertility and female breast cancer (Asif et al., 2021). These results indicated that the safety of sodium p-hydroxybenzoate is higher than that of p-HBA.

Body weight and food intake are typical indicators of adverse effects of drugs on the body (Bilan et al., 2011). Changes in body weight imply that the administered chemical might be toxic to the experimental animals (Teo et al., 2002). In the present experiment, our results showed that no significant differences in body weight or food consumption developed between the control and treated groups during the experimental period. These findings suggested that sodium p-hydroxybenzoate does not influence the body weight or food consumption of experimental animals in the present study. However, the final weight difference is big among the male and female rats. Despite this, the weight gain of males and females rats has sustained the normal range during the study period (Lira et al., 2020; Won et al.,

### Table 10 | Histopathological findings of SD rats treated with sodium p-hydroxybenzoate for 90 days.

| sodium p-hydroxybenzoate (mg/kg) | 0  | 125 | 250 | 500 |
|----------------------------------|----|-----|-----|-----|
| Organs                           | NO. of animals examined | 10 | 10 | 10 | 10 |
| Males                            |                              |    |    |    |    |
| Heart                            | Edema of myocardial interstitium, minimal | 0 | − | − | 2 |
| Liver                            | Congestion, hepatic sinusoids, slight/ Vacular degeneration, minimal | 1 | 1 | 1 | 2 |
| Lung                             | Congestion, minimal          | 0 | 0 | 0 | 2 |
| Spleen                           | Congestion, minimal          | 1 | 2 | 2 | 2 |
| Stomach                          | Inflammation, minimal        | 0 | − | − | 2 |
| Intestine                        | Infiltration, lymphocytes cell, minimal | 2 | 2 | 2 | 3 |
| Females                          |                              |    |    |    |    |
| Liver                            | Congestion, hepatic sinusoids, slight/ Vacular degeneration, minimal | 0 | − | − | 1 |
| Lung                             | Congestion, moderate         | 2 | 2 | 1 | 3 |
| Spleen                           | Congestion, minimal          | 2 | 3 | 3 | 3 |
| Stomach                          | Erosion/Ulcer, minimal       | 0 | − | − | 2 |
| Intestine                        | Infiltration, lymphocytes cell, minimal | 3 | 3 | 3 | 4 |

**Figure 4** | Representative microscopic evaluation (H&E staining) of heart, brain, spleen and lung tissues of rats administered control and 500 mg/kg BW/day sodium p-hydroxybenzoate to male and female SD rats (scale bar = 200 μm).
The basal metabolism and energy expenditure of male rats is higher than that of female rats, which may be the reason for the large difference in final body weight. In addition, all experimental subjects exhibited a similar and slightly decreasing trend in feed consumption, we speculate that except for satisfying own consumption and basal metabolism, some feed was stored as fat and other substances in the body. The foraging amount decreased with the storage amount over time.

Hematological parameters are important indicators of the physiological and pathological status of the body, such as white blood cell (WBC), red blood cell count (RBC), and platelet count (PLT) (Li et al., 2021). Significant changes (either increases or decreases) are due to the influence of the administered compound on the animals (Obakiro et al., 2021). In the present study, there were several statistically significant differences detected in hematological parameters at the end of the experiment in males in the 500 mg/kg BW/day dose group compared to controls, such as white blood cells (WBCs) and prothrombin time (PT). It is well documented that white blood cells are effective markers of inflammation (Karino et al., 2015). These results indicated that the 500 mg/kg BW/day dose may cause hematological toxicity in male rats.

Clinically, various adverse effects of nonsteroidal anti-inflammatory drugs have been reported, including gastrointestinal symptoms, renal injury, liver injury and other symptoms. Therefore, evaluating liver function is very important and is usually assessed by hematological and biochemical parameters, no statistically significant differences were observed, such as slight edema and degeneration of renal tubular epithelial cells in the 500 mg/kg BW/day group in males. These changes were considered adverse effects of sodium p-hydroxybenzoate in the kidneys of males.

Usually, comparison of the organ weights was used to evaluate the toxic effect of the test compound in toxicological experiments (Michael et al., 2007). In the present study, the absolute weight of the liver in females was significantly increased in the 500 mg/kg BW/day group compared to the control group. The changes observed in absolute weight of the liver might be toxicologically relevant.

In the liver, vacuolated degeneration was observed in both sexes in the 500 mg/kg BW/day group. Meanwhile, the number of white blood cells (WBCs) was increased in males, and the absolute weight of the liver was increased in females. All of these changes were likely related to sodium p-hydroxybenzoate administration.

In conclusion, sodium p-hydroxybenzoate administration resulted in slight hepatic or kidney toxicities in both males and females receiving 500 mg/kg BW/day. These changes were systemically observed and considered to be adverse effects associated with sodium p-hydroxybenzoate. Therefore, in the 90-days subchronic toxicological study, the NOAEL for sodium p-hydroxybenzoate was determined to be 250 mg/kg BW/day for both male and female SD rats. The present study is the first report of a safety assessment of
sodium p-hydroxybenzoate. This paper found that sodium p-hydroxybenzoate is safe and has little effect on vital organs, so we speculate that sodium p-hydroxybenzoate is higher security than p-HBA. The clinical use of sodium p-hydroxybenzoate requires a good level of safety, and these results provide a foundation for future preclinical and clinical studies. We will investigate the carcinogenic studies in the future, enabling this research to become more complete.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

All procedures in this experiment were strictly reviewed and approved by the Animal Ethics Committee of Guilin Medical University (animal protocol approval number, GLMC2017030111).

**AUTHOR CONTRIBUTIONS**

XF, YW, and XD contributed to concept and design of the study, HS collected the rat samples, XX and XL performed the statistical analysis, XF wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (82160615), the Natural Science Foundation of Guangxi (2017GXNSFBA198104, 2018GXNSFFA138098, 2019GXNSFBA245104), the special funding for 2017 Guangxi BaGuai Scholars and Guangxi Science and Technology Base and Talent Special Fund (gui ke AD19110123, gui ke AD18281016).

**REFERENCES**

Adyemee, O. O., Akindele, A. J., Yemitan, O. K., Aigbe, F. R., and Fagbo, F. I. (2010). Anticonvulsant, Anxiolytic and Sedative Activities of the Aqueous Root Extract of Securidaca Longepedunculata Frensen. *J. Ethnopharmacol.* 130 (2), 191–195. doi:10.1016/j.jep.2010.04.028

Akindele, A. J., Adeneye, A. A., Salau, O. S., Soﬁdiya, M. O., and Benebo, A. S. (2014). Dose and Time-dependent Sub-chronic Toxicity Study of Hydroethanolic Leaf Extract of Flabellaria Paniculata Cav. (Malpighiaceae) in Rodents. *Front. Pharmacol.* 5, 78. doi:10.3389/fphar.2014.00078

Altman, R., Bosch, B., Brune, K., Patrignani, P., and Young, C. (2015). Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology. *Drugs* 75 (8), 859–877. doi:10.1007/s40265-015-0392-z

Asif, A. H., Rafique, N., Hirani, R. A. K., Wu, H., Shi, L., and Sun, H. (2021). Heterogeneous Activation of Peroxymonosulfate by Co-doped Fe2O3 Nanospheres for Degradation of P-Hydroxybenzoic Acid. *J. Colloid Interf. Sci.* 604, 390–401. doi:10.1016/j.jcis.2021.06.161

Balogun, S. O., da Silva, I. F., Jr., Cololde, E. M., de Oliveira, R. G., Martins, D. T., and Martins, D. T. (2014). Toxicological evaluation of hydroethanolic extract of Helicteres sacarolha A. St.- Hil. et al. *J. Ethnopharmacol.* 157, 285–291. doi:10.1016/j.jep.2014.09.013

CNRThala, N., Emberston, J., Merhi, A., Abramson, S., Arber, N., Baron, J. A., et al. (2013). Vascular and Upper Gastrointestinal Effects of Non-steroidal Anti-inflammatory Drugs: Meta-Analyses of Individual Participant Data from Randomised Trials. *Lancet* 382 (9894), 769–779. doi:10.1016/S0140-6736(13)60900-9

Bilan, V. P., Salah, E. M., Bastacky, S., Jones, H. B., Mayers, R. M., Zinker, B., et al. (2011). Diabetic Nephropathy and Long-Term Treatment Effects of Rosiglitazone and Enalapril in Obese ZSF1 Rats. *J. Endocrinol.* 210 (3), 293–308. doi:10.1530/JOE-11-0122

Costa-Silva, J. H., Lima, C. R., Silva, E. J., Araújo, A. V., Fraga, M. C., Ribeiro E Ribeiro, A., et al. (2008). Acute and Subacute Toxicity of the Carapa Guianensis Aublet (Meliaceae) Seed Oil. *J. Ethnopharmacol.* 116 (3), 495–500. doi:10.1016/j.jep.2007.12.016

Gao, Y., Li, C., Wang, Y., Liu, Y., Li, G., Fan, X., et al. (2017). Nonclinical Safety of Astilbin: A 4-week Oral Toxicity Study in Rats with Genotoxicity, Chromosomal Aberration, and Mammalian Micronucleus Tests. *Food and Chemical Toxicology.* 107, 1–9. doi:10.1016/j.fct.2017.06.024

Garcia, T., Lafuente, D., Blanco, J., Sánchez, D. J., Sirvent, J. J., Domingo, J. L., et al. (2016). Oral Subchronic Exposure to Silver Nanoparticles in Rats. *Food Chem. Toxicol.* 92, 177–187. doi:10.1016/j.fct.2016.04.010

Gowda, S., Desai, P. B., Kulkarni, S. S., Hull, V. V., Math, A. A., and Vernekar, S. N. (2010). Markers of Renal Function Tests. *N. Am. J. Med. Sci.* 2 (4), 170–173. Available at https://pubmed.ncbi.nlm.nih.gov/22624135/

Kapoor, M. P., Moriwaki, M., Timm, D., Yamagata, H., Maruyama, G., Nishihara, Y., et al. (2021). 13-Weeks Subchronic Toxicity of Isoquercitrin-γ-Cyclodextrin (IQC-γcd) Molecular Inclusion Complex in Sprague-Dawley Rats. *Food Chem. Toxicol.* 152, 112217. doi:10.1016/j.fct.2021.112217

Kario, S., Willcox, B. J., Fong, K., Lo, S., Abbott, R., and Masaki, K. H. (2015). Total and Differential white Blood Cell Counts Predict Eight-Year Incident Coronary Heart Disease in Elderly Japanese-American Men: the Honolulu Heart Program. *Atherosclerosis* 238 (2), 153–158. doi:10.1016/j.atherosclerosis.2014.12.003

Kim, H., Kim, S. Y., Sim, G. Y., and Ahn, J. H. (2020). Synthesis of 4-Hydroxybenzoic Acid Derivatives in Escherichia coli. *J. Agric. Food Chem.* 68 (36), 9743–9749. doi:10.1021/acs.jafc.0c03149

Kuo, H. W., Tsai, S. S., Tiao, M. M., Liu, Y. C., Lee, I. M., and Yang, C. Y. (2010). Analgesic Use and the Risk for Progression of Chronic Kidney Disease. *Pharmacoeconomol. Drug Saf.* 19 (7), 745–751. doi:10.1002/pds.1962

Li, F., Wang, L., Cai, Y., Luo, Y., and Shi, X. (2021). Safety Assessment of Desaminotyrosine: Acute, Subchronic Oral Toxicity, and its Effects on Intestinal Microbiota in Rats. *Toxicol. Appl. Pharmacol.* 417, 115464. doi:10.1016/j.taap.2021.115464

Li, I. C., Chen, Y. L., Lee, L. Y., Chen, W. P., Tsai, Y. T., Chen, C. C., et al. (2014). Evaluation of the Toxicological Safety of Erinacine A-Enriched Hericium erinaceus in a 28-day Oral Feeding Study in Sprague-Dawley Rats. *Food Chem. Toxicol.* 70, 61–67. doi:10.1016/j.fct.2014.04.040

Lira, A. C., Prieto, A. I., Baños, A., Guíllemón, E., Moyano, R., Jos, A., et al. (2020). Safety Assessment of Propyl-Propano-Thiosulfonate (PTSO): 90-days Oral Subchronic Toxicity Study in Rats. *Food Chem. Toxicol.* 144, 111612. doi:10.1016/j.fct.2020.111612

Liu, J., Wang, T., Huang, B., Zhuang, Y., Hu, Y., and Fei, P. (2021). Pectin Modified with Phenolic Acids: Evaluation of Their Emulsification Properties, Antioxidation Activities, and Antibacterial Activities. *Int. J. Biol. Macromol.* 174, 485–493. doi:10.1016/j.ijbiomac.2021.01.190

Michael, B., Yano, B., Sellers, R. S., Perry, R., Morton, D., Roome, N., et al. (2007). Evaluation of Organ Weights for Rodent and Non-rodent Toxicity Studies: a Review of Regulatory Guidelines and a Survey of Current Practices. *Toxicol. Pathol.* 35 (5), 742–750. doi:10.1080/01926230701595292
Fan et al. Toxicity of Sodium p-Hydroxybenzoate

Saha, A., Bajpai, A., Krishna, V., and Bhattacharya, S. (2021). Evolving Paradigm of Prothrombin Time Diagnostics with its Growing Clinical Relevance towards Cardio-Compromised and COVID-19 Affected Population. Sensors (Basel) 21 (8), 2636. doi:10.3390/s21082636

Simon, G., Heckmann, V., Töth, D., Pauka, D., Petrus, K., and Molnár, T. F. (2020). The Effect of Hepatic Steatosis and Fibrosis on Liver Weight and Dimensions. Leg. Med. (Tokyo) 47, 101781. doi:10.1016/j.legalmed.2020.101781

Spatafora, C., and Tringali, C. (2012). Natural-derived Polyphenols as Potential Anticancer Agents. Anticancer Agents Med. Chem. 12 (8), 902–918. doi:10.2174/1871521012802649996

Teo, S., Stirling, D., Thomas, S., Hoberman, A., Kiropes, A., and Khetani, V. (2002). A 90-day Oral Gavage Toxicity Study of D-Methylphenidate and DL-methylphenidate in Sprague-Dawley Rats. Toxicology 179 (3), 183–196. doi:10.1016/s0300-4884(02)00338-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Fan, Song, Xu, Lu, Wang and Duan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.